The Gumboro Disease Market is estimated to be valued at USD 338.9 Mn in 2026 and is expected to reach USD 584.6 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 8.1% from 2026 to 2033. The market is witnessing steady growth primarily driven by expansion of commercial poultry production, increasing risk of Infectious Bursal Disease (IBD) outbreaks, rising adoption of preventive poultry vaccination programs, and wider use of conventional, immune-complex, and recombinant/vector vaccines. Gumboro disease, also known as Infectious Bursal Disease (IBD), is a highly contagious viral disease primarily affecting young chickens and can cause significant immunosuppression, strengthening the need for effective disease-prevention and vaccination programs.

The market includes a range of vaccine approaches such as conventional vaccines, antibody/antigen complex vaccines, and vectored vaccines. Conventional vaccines, including live-attenuated and inactivated vaccines, continue to form an important part of established poultry immunization programs, while immune-complex and recombinant/vector vaccines are gaining importance owing to their suitability for hatchery vaccination and advanced disease-control strategies.

Commercial poultry producers are increasingly focusing on preventive vaccination, hatchery-level immunization, disease surveillance, and strain monitoring to protect broiler and layer populations from evolving IBDV strains. Advances in recombinant and multivalent poultry vaccines are further supporting vaccination efficiency by enabling protection against Gumboro disease alongside other major poultry diseases through simplified vaccination schedules. The emergence of next-generation DNA and nanoparticle-based vaccine platforms also represents an important technological development within the market.

Market Dynamics

The Gumboro Disease Market is witnessing significant momentum owing to the continued expansion of global commercial poultry production and flock sizes. Growth in intensive broiler, layer, and breeder production increases the number of birds requiring routine preventive vaccination against Infectious Bursal Disease. The high turnover of commercial poultry populations, particularly broilers, creates recurring demand for vaccination during hatchery and early-life stages. Increasing preventive vaccination and the need to maintain flock health are therefore strengthening demand for Gumboro disease vaccines.

The continued genetic evolution of Infectious Bursal Disease Virus (IBDV) is another major factor influencing market development. Novel variant and highly virulent strains can result in significant bursal damage and immunosuppression, while antigenic changes may reduce the effectiveness of existing vaccination programs. This is increasing the importance of molecular surveillance, strain monitoring, vaccine updates, and broader-protection vaccination strategies.

Technological developments are also supporting market expansion. Recombinant, vectored, immune-complex, and multivalent poultry vaccines are increasingly being incorporated into commercial vaccination strategies. These technologies can improve hatchery vaccination efficiency and facilitate broader disease protection. At the same time, research into DNA vaccines, lipid nanoparticle delivery systems, and other next-generation vaccine approaches is creating opportunities for improved protection against emerging IBDV variants.

The market is also influenced by increasing regulatory emphasis on vaccine quality, manufacturing controls, traceability, and veterinary medicinal product compliance. Updated manufacturing requirements for veterinary biological and immunological medicines are expected to strengthen product quality and confidence, although manufacturers may face higher validation, documentation, quality-control, and compliance requirements.

However, high vaccine development and manufacturing costs remain an important market challenge. In addition, the emergence of new and highly virulent IBDV strains creates continuous pressure on vaccine manufacturers and poultry producers to update disease-management and vaccination strategies.

Key Features of the Study

• This report provides in-depth analysis of the Gumboro Disease Market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Gumboro Disease Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Ceva, ROMVAC Company SA, PTSanbe Farma, Jiangyin Caina Technology co. limited, Cios Co., Salfarm Danmark A/s., Vetbiochem, and others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Gumboro Disease Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Gumboro Disease Market

Market Segmentation

• By Species Type (Revenue, USD Mn, 2026-2033)
  • Broilers
  • Layers
• By Vaccine Type (Revenue, USD Mn, 2026-2033)
  • Conventional Vaccines
  • Antibody/ Antigen Complex Vaccines
  • Vectored Vaccines
• Global Gumboro Disease Market, By Region (Revenue, USD Mn, 2026-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Ceva
  • ROMVAC Company SA
  • PTSanbe Farma
  • Jiangyin Caina Technology co. limited
  • Cios Co.
  • Salfarm Danmark A/s.
  • Vetbiochem
  • Others